MGNX Dec 2024 2.000 call
| Previous close | 1.7500 |
| Open | N/A |
| Bid | 0.9000 |
| Ask | 4.0000 |
| Strike | 2.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.7500 - 1.7500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Simply Wall St.Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
ZacksCapricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
GlobeNewswireMacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohortCompany expects to have mature median rPFS no later than early 2025MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8
